文献速递膀胱癌与上尿路尿路上皮癌

中危非肌层浸润性膀胱癌的条件无复发生存与无进展生存及亚分类影响

Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
PubMed 文献 · BJU Int · 2020-09-21

该回顾性队列纳入602例经尿道膀胱肿瘤电切术且病理诊断为中危非肌层浸润性膀胱癌的患者。条件无复发生存率随无复发生存时间延长而改善,但条件无进展生存率未随时间改善。基于复发肿瘤、多发肿瘤和肿瘤大小三个临床病理因素的亚分类可分层条件复发风险,支持制定不同监测方案。

要点

  • 中危NMIBC条件无复发生存率随时间延长改善,条件无进展生存率未改善。
  • 复发肿瘤、多发肿瘤、肿瘤>3 cm、术后即刻灌注化疗和BCG是基线复发独立预测因素。
  • 基于三个临床病理因素的亚分类可分层1、3、5年条件复发风险,支持不同监测方案。

核心结论

  • 中危NMIBC患者条件无复发生存率随时间变化,而无进展生存率不随时间变化。
  • 基于临床病理因素亚分类的中危NMIBC支持制定不同监测方案。

研究设计与样本

  • 回顾性队列研究纳入602例接受经尿道膀胱肿瘤电切术且组织病理学诊断为中危NMIBC的患者。

主要发现

  • 条件无复发生存率在1、2、3、4和5年随无复发生存时间延长而改善,但条件无进展生存率未随时间改善。
  • 多变量分析显示复发肿瘤、多发肿瘤、肿瘤大小>3 cm、术后即刻膀胱灌注化疗和BCG给药是基线复发的独立预测因素。
  • 这些因素的预测能力随无复发生存时间延长而消失。
  • 基于复发肿瘤、多发肿瘤和肿瘤大小三个因素将患者分为三组,高IR组(两个因素)基线RFS显著差于中IR组(一个因素,P < 0.001)和低IR组(无因素,P = 0.005)。
  • 该亚分类在1、3和5年也可分层条件复发风险。

关键数值与推荐

  • 高IR组(两个因素)基线RFS显著差于中IR组(一个因素,P < 0.001)。
  • 高IR组(两个因素)基线RFS显著差于低IR组(无因素,P = 0.005)。

临床怎么用

  • 对中危NMIBC患者可基于复发肿瘤、多发肿瘤和肿瘤大小进行亚分类以分层条件复发风险。
  • 亚分类结果可为制定不同监测方案提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), and to examine the predictive factors for recurrence at different time points by assessing conditional RFS and PFS. PARTICIPANTS AND METHODS: A cohort of 602 patients treated with transurethral resection of bladder tumour and histopathologically diagnosed with IR NMIBC was included in this retrospective study. RESULTS: The conditional RFS rate at 1, 2, 3, 4 and 5 years improved with increased duration of RFS; however, the conditional PFS rate did not improve over time. Multivariable analyses showed that recurrent tumour, multiple tumours, tumour size (>3 cm), immediate postoperative instillation of chemotherapy, and administration of BCG were independent predictive factors for recurrence at baseline. The predictive ability of these factors disappeared with increasing recurrence-free survivorship. Subclassification of these patients with IR NMIBC into three groups using clinicopathological factors (recurrent tumour, multiple tumours, tumour size) demonstrated that the high IR group (two factors) had significantly worse RFS than the intermediate (one factor, P < 0.001) and low IR groups (no factor, P = 0.005) at baseline. This subclassification stratified conditional risk of RFS also at 1, 3 and 5 years, which provides the basis for distinct surveillance protocols among patients with IR NMIBC. CONCLUSION: Conditional survival analyses of patients with IR NMIBC demonstrate that RFS changes over time, while PFS does not change. These data support distinct surveillance protocols based on the subclassification of IR NMIBC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kohada Y, Hayashi T, Hsi RS, et al. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. BJU Int. 2020. PMID: 32805763. doi:10.1111/bju.15209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。